{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:40:35Z","timestamp":1759207235601,"version":"3.44.0"},"reference-count":33,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: It is not clear if the administration of iodine-131 in patients with differentiated thyroid cancers induces relevant cystitis and lower urinary tract infections (UTIs). The aim of this study was to evaluate the impact of oral administration of hyaluronic acid and chondroitin sulphate (HA&amp;CS) on the frequency of UTIs induced by iodine-131. Methods: In this study, 166 female patients with a surgical diagnosis of differentiated thyroid cancer who were hospitalized in Sant \u2019Andrea Hospital of Rome to undergo the first cycle of therapy with iodine-131 for thyroid remnant ablation were evaluated. Sixty-one patients were treated with HA&amp;CS for 8 days, and thirty-nine patients were treated with HA&amp;CS for 17 days. Sixty-six patients were not treated with HA&amp;CS and were used as control subjects. Patients underwent urinalysis at different time points: immediately before 131I therapy, two days later, and one week later. Patients were divided in six groups based on whether they received the treatment with HA&amp;CS, its duration, and whether they developed a UTI: group A, n = 51 patients who did not receive HA&amp;CS and did not develop UTI; group B1, n = 37 patients treated with HA&amp;CS for 8 days and did not develop UTI; group B2, n = 29 patients treated with HA&amp;CS for 17 days and did not develop UTI; group C, n = 15 patients who did not receive HA&amp;CS and developed UTI; group D1, n = 24 patients treated with HA&amp;CS for 8 days and developed UTI; group D2, n = 10 patients treated with HA&amp;CS for 17 days and developed UTI. Results: The bacteria count, red blood cells and white blood cells did not change when group A was compared to both group B1 and group B2, while pH and epithelial cells showed a decrease over time when comparing group A and group B2 (p = 0.01 and p &lt; 0.0001, respectively). Comparing group C with group D1 and group D2, patients who did not receive HA&amp;CS (group C) showed a higher bacteria and epithelial cell count compared to those who were pre-treated with HA&amp;CS. Conclusions: HA&amp;CS could be an effective supportive therapy to prevent and mitigate UTIs in patients treated with 131I.<\/jats:p>","DOI":"10.3390\/cancers17193154","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:40:52Z","timestamp":1759146052000},"page":"3154","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Hyaluronic Acid and Chondroitin Sulphate in Protecting Urinary Epithelium in Patients Operated for Differentiated Thyroid Cancer Undergoing Ablation Therapy with Iodine-131"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1884-9171","authenticated-orcid":false,"given":"Giuseppe","family":"Campagna","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit, Department Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, \u201cSapienza\u201d University of Rome, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-5059","authenticated-orcid":false,"given":"Chiara","family":"Lauri","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, \u201cSapienza\u201d University of Rome, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Lanzolla","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, University Hospital \u201cSant\u2019Andrea\u201d, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Festa","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, University Hospital \u201cSant\u2019Andrea\u201d, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7880-383X","authenticated-orcid":false,"given":"Luciano","family":"Carideo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, \u201cSapienza\u201d University of Rome, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-648X","authenticated-orcid":false,"given":"Alberto","family":"Signore","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, \u201cSapienza\u201d University of Rome, 00189 Rome, Italy"},{"name":"Nuclear Medicine Unit, University Hospital \u201cSant\u2019Andrea\u201d, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,28]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Matrone, A., Campopiano, M.C., Nervo, A., Sapuppo, G., Tavarelli, M., and De Leo, S. (2020). Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine. Front. Endocrinol., 10.","key":"ref_1","DOI":"10.3389\/fendo.2019.00884"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/1450-1147.163240","article-title":"Radioiodine Remnant Ablation: A Critical Review","volume":"14","author":"Bal","year":"2015","journal-title":"World J. Nucl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","article-title":"Guidelines for radioiodine therapy of differentiated thyroid cancer","volume":"35","author":"Luster","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000468927","article-title":"Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity","volume":"6","author":"Andresen","year":"2017","journal-title":"Eur. Thyroid. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.zemedi.2022.10.001","article-title":"Determinants of target absorbed dose in radionuclide therapy","volume":"33","author":"Lassmann","year":"2023","journal-title":"Z. F\u00fcr Med. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2967\/jnumed.121.262305","article-title":"Dosimetry in radiopharmaceutical therapy","volume":"63","author":"Zanzonico","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/MNM.0000000000000132","article-title":"Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma","volume":"35","author":"Fallahi","year":"2014","journal-title":"Nucl. Med. Commun."},{"doi-asserted-by":"crossref","unstructured":"Van Nostrand, D., Freitas, J.E., Sawka, A.M., and Tsang, R.W. (2016). Side effects of 131I for therapy of differentiated thyroid carcinoma. Thyroid Cancer: A Comprehensive Guide to Clinical Management, Springer.","key":"ref_9","DOI":"10.1007\/978-1-4939-3314-3_62"},{"key":"ref_10","first-page":"9","article-title":"Impact of Ialuril Soft Gels in reducing urinary toxicity during radical hypofractionated radiotherapy in prostate cancer: A preliminary experience","volume":"68","author":"Fersino","year":"2016","journal-title":"Minerva Urol. Nefrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pathophysiology29030028","article-title":"Oral Preparation of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin (Ialuril\u00ae Soft Gels) for the Prevention of LUTS after Intravesical Chemotherapy","volume":"29","author":"Manfredi","year":"2022","journal-title":"Pathophysiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14787210.2025.2487162","article-title":"Adding collagen, propolis plus quercetin, bacillus coagulans, hyaluronic acid and chondroitin sulphate to D-mannose avoids symptoms and prevents recurrence in women with recurrent urinary tract infections: A single-blind randomized controlled trial","volume":"23","author":"Riemma","year":"2025","journal-title":"Expert. Rev. Anti-Infect. Ther."},{"doi-asserted-by":"crossref","unstructured":"Crocetto, F., Balsamo, R., Amicuzi, U., De Luca, L., Falcone, A., Mirto, B.F., Giampaglia, G., Ferretti, G., Capone, F., and Machiella, F. (2023). Novel key ingredients in urinary tract health\u2014The role of D-mannose, chondroitin sulphate, hyaluronic acid, and N-acetylcysteine in urinary tract infections (Uroial PLUS\u00ae). Nutrients, 15.","key":"ref_13","DOI":"10.3390\/nu15163573"},{"doi-asserted-by":"crossref","unstructured":"Stellavato, A., Pirozzi, A.V., Diana, P., Reale, S., Vassallo, V., Fusco, A., Donnarumma, G., De Rosa, M., and Schiraldi, C. (2019). Hyaluronic acid and chondroitin sulfate, alone or in combination, efficiently counteract induced bladder cell damage and inflammation. PLoS ONE, 14.","key":"ref_14","DOI":"10.1371\/journal.pone.0218475"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejogrb.2016.10.018","article-title":"Efficacy of an orally administered combination of hyaluronic acid, chondroitin sulfate, curcumin and quercetin for the prevention of recurrent urinary tract infections in postmenopausal women","volume":"207","author":"Torella","year":"2016","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jsxmed\/qdae052","article-title":"Oral preparation of hyaluronic acid, chondroitin sulfate, N-acetylglucosamine, and vitamin C improves sexual and urinary symptoms in participants with recurrent urinary tract infections: A randomized crossover trial","volume":"21","author":"Boeri","year":"2024","journal-title":"J. Sex. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1080\/10790268.2022.2089816","article-title":"Intravesical hyaluronic acid with chondroitin sulphate to prevent urinary tract infection after spinal cord injury","volume":"46","author":"King","year":"2023","journal-title":"J. Spinal Cord. Med."},{"doi-asserted-by":"crossref","unstructured":"Rahnama\u2019i, M.S., Javan Balegh Marand, A., R\u00f6schmann-Doose, K., Steffens, L., and Arendsen, H.J. (2022). The efficacy and safety of intravesical chondroitin sulphate solution in recurrent urinary tract infections. BMC Urol., 22.","key":"ref_18","DOI":"10.1186\/s12894-022-01149-7"},{"doi-asserted-by":"crossref","unstructured":"Shabbir, U., Rubab, M., Daliri, E.B., Chelliah, R., Javed, A., and Oh, D.H. (2021). Curcumin, quercetin, catechins and metabolic diseases: The role of gut microbiota. Nutrients, 13.","key":"ref_19","DOI":"10.3390\/nu13010206"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s13346-014-0199-6","article-title":"Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin","volume":"4","author":"Grill","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_21","first-page":"5277","article-title":"Efficacy of quercetin against polymicrobial biofilm on catheters","volume":"13","author":"Hamzah","year":"2020","journal-title":"Res. J. Pharm. Technol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1134\/S0003683824608060","article-title":"In vitro Evaluation of the Combinatory Antibacterial and Antiproliferative Effects of Ciprofloxacin and Curcumin\u2013Quercetin Mixture","volume":"61","year":"2025","journal-title":"Appl. Biochem. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clgc.2016.01.016","article-title":"Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Improves Symptoms of Postradiation Cystitis: Prospective Pilot Study","volume":"14","author":"Gacci","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2147\/CMAR.S357814","article-title":"Hypofractionated Postoperative Radiotherapy in Prostate Cancer with Ialuril Soft Gels\u00ae: Toxicity and Efficacy Analysis on a Retrospective Series of 305 Patients","volume":"14","author":"Nicosia","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5301\/uro.5000185","article-title":"New preclinical data\u2014The case for Ialuril\u00ae","volume":"83","author":"Salonia","year":"2016","journal-title":"Urologia"},{"key":"ref_26","first-page":"121","article-title":"Hyaluronic acid-chondroitin sulfate: A potential factor to select pure stress urinary incontinence in patients with interstitial cystitis\u2044painful bladder syndrome and mixed incontinence symptoms","volume":"67","author":"Morelli","year":"2015","journal-title":"Minerva Ginecol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E721","DOI":"10.5489\/cuaj.1989","article-title":"Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey","volume":"8","author":"Cicione","year":"2014","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_28","first-page":"1515","article-title":"Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with 131I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation","volume":"63","author":"Signore","year":"2022","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/mutage\/15.1.69","article-title":"Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy","volume":"15","author":"Oliveira","year":"2000","journal-title":"Mutagenesis"},{"doi-asserted-by":"crossref","unstructured":"Buczy\u0144ska, A., Sidorkiewicz, I., Rogucki, M., Siewko, K., Adamska, A., Ko\u015bciuszko, M., Maliszewska, K., Koz\u0142owska, G., Szumowski, P., and My\u015bliwiec, J. (2021). Oxidative stress and radioiodine treatment of differentiated thyroid cancer. Sci. Rep., 11.","key":"ref_30","DOI":"10.1038\/s41598-021-96637-5"},{"doi-asserted-by":"crossref","unstructured":"Yang, L., Ma, J., Lei, P., Yi, J., Ma, Y., Huang, Z., Wang, T., Ping, H., Ruan, D., and Sun, D. (2023). Advances in Antioxidant Applications for Combating 131I Side Effects in Thyroid Cancer Treatment. Toxics, 11.","key":"ref_31","DOI":"10.3390\/toxics11060529"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.4238\/2014.March.31.5","article-title":"Antimutagenic and radioprotective activities of beta-carotene against the biological effects of iodine-131 radiopharmaceutical in Wistar rats","volume":"13","author":"Berti","year":"2014","journal-title":"Genet. Mol. Res. GMR"},{"doi-asserted-by":"crossref","unstructured":"Vrinceanu, D., Dumitru, M., Marinescu, A., Serboiu, C., Musat, G., Radulescu, M., Popa-Cherecheanu, M., Ciornei, C., and Manole, F. (2024). Management of Giant Thyroid Tumors in Patients with Multiple Comorbidities in a Tertiary Head and Neck Surgery Center. Biomedicines, 12.","key":"ref_33","DOI":"10.3390\/biomedicines12102204"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3154\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:17:47Z","timestamp":1759205867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,28]]},"references-count":33,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193154"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193154","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,9,28]]}}}